Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23115813 | 0.85 | SMN1; SMN2 (0.45) | CYP1A2IDO1TDO2KMT2A | |
| SCHEMBL29766050 | 0.83 | IDO1 (0.41) | IDO1TDO2HSD17B10KMT2A | |
| SCHEMBL456673 | 0.83 | IDO1 (0.41) | IDO1TDO2HSD17B10KMT2A | |
| SCHEMBL12499367 | 0.83 | CREBBP (0.42) | CYP1A2CYP2C19L3MBTL1OPRK1IRAK4 | |
| SCHEMBL2591387 | 0.82 | PDE1A (0.40) | L3MBTL1OPRK1PDE1CHSD17B10KMT2A | |
| SCHEMBL4721058 | 0.82 | PDE1C (0.38) | CYP1A2CYP2C19L3MBTL1OPRK1PDE1C | |
| SCHEMBL23115827 | 0.82 | IDO1 (0.41) | IDO1TDO2HSD17B10KMT2A | |
| SCHEMBL2588056 | 0.82 | EZH2 (0.48) | L3MBTL1OPRK1PDE1CIRAK4CYP11B2 | |
| SCHEMBL31474829 | 0.82 | EZH2 (0.48) | L3MBTL1OPRK1PDE1CIRAK4CYP11B2 | |
| SCHEMBL2595724 | 0.82 | OPRK1 (0.45) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2406255-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | Glaxo Group Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102958-A1 | 4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CYP1A2 4522/4885CYP2C19 4852/4885IDO1 4420/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | CYP1A2 1522/4885CYP2C19 2386/4885IDO1 113/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | CYP1A2 4125/4885CYP2C19 4792/4885IDO1 253/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | CYP1A2 4125/4885CYP2C19 4792/4885IDO1 253/4885 |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | CYP1A2 3119/4885CYP2C19 2115/4885IDO1 1459/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | CYP1A2 3383/4885CYP2C19 4578/4885IDO1 58/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | CYP1A2 4125/4885CYP2C19 4792/4885IDO1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.